tetano
Editor, Senior Moderator
Dermatol Ther
. 2020 Jul 8.
doi: 10.1111/dth.13986. Online ahead of print.
Cutaneous Manifestations and Considerations in COVID-19 Pandemic: A Systematic Review
Farnoosh Seirafianpour[SUP] 1 [/SUP], Sogand Sodagar[SUP] 1 [/SUP], Arash Pour Mohammad[SUP] 1 [/SUP], Parsa Panahi[SUP] 1 [/SUP], Samaneh Mozafarpoor[SUP] 2 [/SUP], Simin Almasi[SUP] 3 [/SUP], Azadeh Goodarzi[SUP] 4 [/SUP]
Affiliations
Abstract
Background: COVID-19 had a great impact on medical approaches among dermatologist OBJECTIVE: This systematic review focuses on all skin problems related to COVID-19, including primary and secondary COVID-related cutaneous presentations and the experts recommendations about dermatological managements especially immunomodulators usage issues METHOD: Search was performed on PubMed, Scopus, Embase and ScienceDirect. Other additional resources were searched included Cochrane, WHO, Medscape and coronavirus dermatology resource of Nottingham university. The search completed on May/03/2020. 377 articles assigned to the inclusion and exclusion groups RESULT: Eighty-nine articles entered the review. Primary mucocutaneous and appendageal presentations could be the initial or evolving signs of COVID-19. It could be manifest most commonly as a maculopapular exanthamatous or morbiliform eruption, generalized urticaria or pseudo chilblains recognized as "COVID toes" (pernio-like acral lesions or vasculopathic rashes).
Conclusion: During pandemic, Non-infected non-at risk patients with immune-medicated dermatologic disorders under treatment with immunosuppressive immunomodulators are not needed to alter their regimen or discontinue the therapies. At-risk and infection-suspected patients needed to dose reduction, interval increase or temporary drug discontinuation (at least 2 weeks). Patients with an active COVID-19 infection should hold the biologic or non-biologic immunosuppressives until the complete recovery occur (at least 4 weeks). This article is protected by copyright. All rights reserved.
Keywords: COVID-19; alopecia; biologic; collagen vascular disorder; corona virus; cosmetic procedure; cutaneous; cutaneous manifestation; dermatitis; dermatology; drug reaction; eczema; health care staff; hidradenitis suppurativa; immunobullous; immunomodulator; immunosupressant; immunosupressive; novel human coronavirus (SARS-CoV-2); pandemic considerations; papulosquamous; pemphigus; psoriasis; recommendation; skin; skin manifestation; skin rheumatologic disorder; special; specific skin diseases; surgical procedure; systematic review; systemic treatment; teledermatology; visits.
. 2020 Jul 8.
doi: 10.1111/dth.13986. Online ahead of print.
Cutaneous Manifestations and Considerations in COVID-19 Pandemic: A Systematic Review
Farnoosh Seirafianpour[SUP] 1 [/SUP], Sogand Sodagar[SUP] 1 [/SUP], Arash Pour Mohammad[SUP] 1 [/SUP], Parsa Panahi[SUP] 1 [/SUP], Samaneh Mozafarpoor[SUP] 2 [/SUP], Simin Almasi[SUP] 3 [/SUP], Azadeh Goodarzi[SUP] 4 [/SUP]
Affiliations
- PMID: 32639077
- DOI: 10.1111/dth.13986
Abstract
Background: COVID-19 had a great impact on medical approaches among dermatologist OBJECTIVE: This systematic review focuses on all skin problems related to COVID-19, including primary and secondary COVID-related cutaneous presentations and the experts recommendations about dermatological managements especially immunomodulators usage issues METHOD: Search was performed on PubMed, Scopus, Embase and ScienceDirect. Other additional resources were searched included Cochrane, WHO, Medscape and coronavirus dermatology resource of Nottingham university. The search completed on May/03/2020. 377 articles assigned to the inclusion and exclusion groups RESULT: Eighty-nine articles entered the review. Primary mucocutaneous and appendageal presentations could be the initial or evolving signs of COVID-19. It could be manifest most commonly as a maculopapular exanthamatous or morbiliform eruption, generalized urticaria or pseudo chilblains recognized as "COVID toes" (pernio-like acral lesions or vasculopathic rashes).
Conclusion: During pandemic, Non-infected non-at risk patients with immune-medicated dermatologic disorders under treatment with immunosuppressive immunomodulators are not needed to alter their regimen or discontinue the therapies. At-risk and infection-suspected patients needed to dose reduction, interval increase or temporary drug discontinuation (at least 2 weeks). Patients with an active COVID-19 infection should hold the biologic or non-biologic immunosuppressives until the complete recovery occur (at least 4 weeks). This article is protected by copyright. All rights reserved.
Keywords: COVID-19; alopecia; biologic; collagen vascular disorder; corona virus; cosmetic procedure; cutaneous; cutaneous manifestation; dermatitis; dermatology; drug reaction; eczema; health care staff; hidradenitis suppurativa; immunobullous; immunomodulator; immunosupressant; immunosupressive; novel human coronavirus (SARS-CoV-2); pandemic considerations; papulosquamous; pemphigus; psoriasis; recommendation; skin; skin manifestation; skin rheumatologic disorder; special; specific skin diseases; surgical procedure; systematic review; systemic treatment; teledermatology; visits.